US20180217150A1 - Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability - Google Patents

Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability Download PDF

Info

Publication number
US20180217150A1
US20180217150A1 US15/840,958 US201715840958A US2018217150A1 US 20180217150 A1 US20180217150 A1 US 20180217150A1 US 201715840958 A US201715840958 A US 201715840958A US 2018217150 A1 US2018217150 A1 US 2018217150A1
Authority
US
United States
Prior art keywords
protein
amino acid
molecule
active
loop
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/840,958
Inventor
Joshua S. Salafsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BlueLight Therapeutics Inc
Original Assignee
Biodesy Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biodesy Inc filed Critical Biodesy Inc
Priority to US15/840,958 priority Critical patent/US20180217150A1/en
Assigned to BIODESY, LLC reassignment BIODESY, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SALAFSKY, JOSHUA S.
Assigned to Biodesy, Inc. reassignment Biodesy, Inc. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BIODESY, LLC
Publication of US20180217150A1 publication Critical patent/US20180217150A1/en
Assigned to BLUELIGHT THERAPEUTICS, INC. reassignment BLUELIGHT THERAPEUTICS, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: Biodesy, Inc.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64Fluorescence; Phosphorescence
    • G01N21/6428Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366Apparatus specially adapted for solid-phase testing
    • G01N33/54373Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64Fluorescence; Phosphorescence
    • G01N21/6428Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G01N2021/6439Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
    • G01N2021/6441Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks with two or more labels
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64Fluorescence; Phosphorescence
    • G01N21/6445Measuring fluorescence polarisation
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

A system for making molecules, and proteins in particular, suitable for detection by a surface-selective nonlinear optical technique. A first use of the invention is for determining a protein's structure in real space and real time. A second use of the invention is to detect a protein or its activity (conformational change). A third use of the invention is for drug screening. A further aspect of the present invention is measuring probe tilt angle orientation in an oriented protein.

Description

  • CROSS-REFERENCES
  • This application is a Continuation Application of U.S. application Ser. No. 14/859,742, filed Sep. 21, 2015, now U.S. Pat. No. 9,880,172, which is a Divisional Application of U.S. application Ser. No. 12/535,631, filed Aug. 4, 2009, now U.S. Pat. No. 9,182,406, which claims priority to U.S. Provisional Patent Application Ser. No. 61/137,773, filed Aug. 4, 2008, each of which is incorporated herein by reference in its entirety.
  • INTRODUCTION
  • Surface-selective techniques such as second-harmonic generation (SHG) have recently been applied to the study of proteins at interfaces and protein conformational change by the use of second-harmonic-active labels1-3, which are attached to the surface of the protein. Methods for detecting proteins by SHG or sum-frequency generation (SFG) are disclosed wherein the protein is detected by incorporating an SH-active (or SF-active) unnatural amino acid probe into it.
  • The aim of structure-based drug screening and basic studies of the mechanism of biological molecules requires a tool that can measure structure, and structural change, of biological molecules as they bind to ligands, drugs, etc. Present techniques for determining structural change are mainly confined to NMR (Nuclear Magnetic Resonance) and X-ray crystallography. Neither of these techniques is suitable for measuring structural change in real-time. Moreover, they are time- and labor-intensive and unsuitable for widescale use in drug screening. Furthermore, there are many proteins that are difficult to crystallize (e.g., membrane proteins) and thus whose structures have not been determined.
  • It is often not convenient to label a protein using standard in vitro methods, as it may require single-site mutagenesis to produce an attachment site for the chemical label, or the labeling itself may introduce a perturbative modification to the structure of the protein. Also, it is often not possible to engineer a single, chemically reactive and orthogonal attachment site for a label into a protein; for example, there may be native and reactive cysteine groups in the case of sulfhydryl-bearing labels. Furthermore, for the purpose of measuring conformational change using a surface-selective nonlinear detection technique such as second-harmonic generation (SHG) or sum-frequency generation (SFG), it is desirable to have the probe (the label) rigidly fixed within the protein frame of reference. Then, movement of the label relative to the protein will be minimized, if not completely eliminated, the signal contrast (i.e., SH signal) between conformations will be maximized, and precise spatial measurements of the probe tilt angle relative to a surface can be used to determine a protein's structure.
  • SUMMARY
  • The present invention includes a system for making molecules, and proteins in particular, suitable for detection by a surface-selective nonlinear optical technique. A first use of the invention is for determining a protein's structure in real space and real time. A second use of the invention is to detect a protein or its activity (conformational change). A third use of the invention is for drug screening. A further aspect of the present invention is measuring probe tilt angle orientation in an oriented protein.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1A shows the structure of Aladan. FIG. 1B shows the structure of GB1 (11). Residues with Aladan substitutions are highlighted: Leu7 and Ala24. Fc and Fab binding surfaces are also shown9,10. FIG. 1C shows an SHG spectrum of Aladan adsorbed to a mica surface, in PBS.
  • FIG. 2A shows an SHG spectrum for GB1-Aladan adsorbing to an aldehyde-derivatized glass coverslip, detected by SHG, and plotted as SHG intensity versus time. FIG. 2B shows an SHG spectrum of the adsorbed protein at steady-state, detected by SHG, and plotted as SHG intensity versus wavelength.
  • FIG. 3 shows a schematic view of the protein A-Fc-GB1 complex binding to the Fc fragment.
  • FIG. 4A shows an SHG spectrum for GB1-Aladan binding to an IgG-Protein A-glass coverslip. As indicated in FIG. 4B, addition of Fc causes a small decrease in SH signal with the Ala24 Aladan mutant, indicating a change in the orientation of Aladan. FIG. 4C shows an SHG spectrum for addition of Fc to the Leu7 Aladan mutant. Signals were detected by SHG and are averaged over 4 seconds. The bars denote the standard error of measurement (SEM).
  • DETAILED DESCRIPTION
  • The invention includes a system for making molecules, and proteins in particular, suitable for detection by a surface-selective nonlinear optical technique. A first use of the invention is for determining a protein's structure in real space and real time. A second use of the invention is to detect a protein or its activity (conformational change). A third use of the invention is for drug screening. A further aspect of the present invention is measuring probe tilt angle orientation in an oriented protein.
  • We introduce a new class of probes—SH-active unnatural amino acids—and demonstrate their use for detecting biomolecules and structural changes by SHG. Aladan is demonstrated to be SH-active by studying it alone on a surface and incorporated into a protein, GB1, rendering the protein detectable. A structural change is observed when an Fc fragment is introduced to GB1, labeled with Aladan at Ala24, and bound to IgG on a surface. No such change is observed if Aladan is substituted at Leu7 instead. These results are consistent with a local conformational change of GB1, a change undetectable by fluorescence or X-ray crystallography. SHG with SH-active exogenous labels or unnatural amino acid probes is promising as a structural technique with high angular and temporal resolution. With a narrowly oriented protein population appropriately labeled, the technique could be used to determine conformational change in real time and space, site-by-site.
  • Second-harmonic generation (SHG) is highly sensitive to the net, average orientation of SH-active molecules on surfaces, and has recently emerged as a technique for detecting biomolecules and their conformational changes. As most biomolecules are not intrinsically SH-active, they must be labeled with probes to render them detectable. To date, exogenous probes have been used to do this, but second-harmonic-active unnatural amino acids offer important advantages for the long-range goal of precisely and directly determining structural changes in real time, and may be used for both buried and surface sites. Results of the first known SH-active unnatural amino acid, Aladan, are presented here. Aladan is found to be SH-active by detecting it at an interface, both alone and incorporated into the B1 domain of protein G (GB1), a globular immunoglobulin-binding protein, at both buried and exposed sites. The tilt angle of Aladan alone adsorbed on a mica surface is determined by polarization experiments, and its nonlinear polarizability α(2) is found to be ca. 10−30 esu. Aladan GB1 mutants are detectable by SHG, either when coupled covalently to a derivatized glass surface or bound to IgG immobilized via protein A. Addition of an Fc domain to this GB1 complex causes a small but defined change in the SH signal when Aladan is incorporated at site Ala24, but not at Leu7, consistent with a local conformational change of GB1. This structural change is not apparent in either X-ray crystallography and fluorescence studies, demonstrating that SHG can detect subtle orientational changes, including protein-protein interactions in which no significant rearrangements occur.
  • Second-harmonic generation (SHG) is well known in the physical sciences for studying molecules on surfaces and is especially useful for measuring orientation. More recently, SHG has emerged as a sensitive technique to detect and study the conformational changes of biomolecules using SH-active probes1.2. Labeled proteins that are adsorbed or covalently immobilized on surfaces produce an SHG signal, which is due to the average, net orientation of the nonlinear polarizability of the SHG label relative to the surface plane. Specifically, the SH intensity is given as ISH=G(χs (2))2 I2, where ISH is the second-harmonic intensity, G is a constant that depends on the experimental geometry and wavelength, and I is the intensity of the fundamental beam. The nonlinear susceptibility, χs (2), carries the details of the SH-active molecules on the surface via the equation:

  • χs (2) =N s(2)>  (1)
  • where Ns is the surface density of the molecules, the brackets denote an orientational average, and α(2) is their nonlinear polarizability, a quantum-mechanical property that determines the probability of producing a second-harmonic photon from two, incident photons of the fundamental beam. Measurements of χs (2) provide information about the orientation of a molecule on the surface. For example, when α(2) is dominated by a single element ζζζ(2) along the molecular axis ζ and the azimuthal distribution of the molecules are random in the plane of the surface, the only elements of χs (2) that do not vanish are:

  • χs⊥⊥⊥ (2) N s<cos 3θ>αζζζ (2)   (2A)

  • χs⊥∥∥ (2)s∥⊥∥ (2)s∥∥⊥ (2)=1/2 N s<cos θ sin 2θ>αζζζ (2)   (2B)
  • where θ is the polar angle between ζ and the surface normal, and the subindices ⊥ and ∥ refer to the directions perpendicular and parallel to the surface, respectively3.
  • The SH light is coherent and directional, so collection and isolation of the SH beam is simplified, and because the fundamental and the second-harmonic are well separated spectrally, cross-talk, which can plague fluorescence measurements, is non-existent with SHG.
  • Photodegradation of the probe occurs relatively slowly via two-photon-induced absorption, allowing measurements over relatively long timescales. The trade-off with SHG is signal strength—it is orders of magnitude weaker than fluorescence. However, only SH-active molecules immobilized on the surface contribute second harmonic light since randomly diffusing molecules near the surface produce no signal; their orientational average, from Equation 1, is zero. Therefore, SHG is intrinsically equipped to discriminate between surface-bound and free molecules.
  • The SH signal reports on the orientational average of the probes, and thus changes due to conformational change. In previous work, ligand-induced conformational changes were detected by monitoring the SH intensity with calmodulin and adenylate kinase adsorbed non-specifically to surfaces1,2. SFG and SHG have also been applied to study protein adsorption phenomena at various interfaces with protein alone or co-adsorbed with an SH-active probe4-8. The current study uses GB1, a well-studied IgG-binding streptococcal protein that has been useful in a variety of structural and biophysical studies. GB1 binds to both the Fab and Fc domains of IgG, and structures of these complexes have been determined9,10, in addition to that of the uncomplexed protein11,12. We have previously incorporated the synthetic amino acid Aladan at multiple sites of GB1 for studies of protein solvation13,14 Like other donor-acceptor fluorophores, Aladan undergoes a large increase in dipole moment upon excitation, leading to significant solvatochromic fluorescence shifts.
  • Unnatural amino acids (UAA's) offer a means of labeling proteins at both buried and exposed sites, and as innate components of the protein they should report on structural changes with more sensitivity and fidelity than probes attached via sidechain-reactive linkers13. We report here that the synthetic amino acid Aladan shows good activity in SHG measurements, making it the first known SH-active UAA. We estimate the free Aladan hyerpolarizability to be ˜10−30 esu and measure the average orientation of Aladan adsorbed on a mica surface as 48°. Incorporated into GB1, we detect the protein when it is covalently coupled to a surface or bound via an IgG-protein A complex. Addition of Fc to the latter system causes a small change in the SH signal when Aladan is substituted at the Ala24 residue, but not at Leu7, consistent with a local change in GB1 conformation.
  • Measurements may be made using any suitable experimental set-ups and techniques. An exemplary set-up has been described previously1,2. Briefly, a Ti:S oscillator (Coherent; Mira 900) pumped by a solid-state DPSS laser (Spectra-Physics; 5W Millenia) was tuned to 780 nm (0.8 W) and focused into a prism (BK-7) that was optically coupled to the coverslips or mica surfaces for total internal reflection (TIR). The incident angle of the fundamental at the surface was 73° (critical angle=61°). A monochromator and color filter were used to remove the fundamental and select the SH signal and its intensity was measured by a PMT. A well for buffer was defined by an adhesive gasket (Grace Biolabs) and filled with phosphate buffered saline (PBS). Human IgG (normal serum) and Fc (IgG-Fc) were obtained from Bethyl Laboratories. Mica (Grade IV) was obtained from SPI Corporation and was freshly cleaved for the experiments. Protein A- and aldehyde-derivatized glass coverslips were obtained from Xenopore Corporation. Aladan and Aladan GB1 mutants (synthesized as described; 13,14 were introduced to the wells at 1 μM; IgG was added at 3 μM; and IgG-Fc was added at 6 μM. GB1-Aladan was immobilized on the aldehyde-derivatized surface by exposing the protein to the surface for several minutes followed by washing with buffer. For the experiments with IgG, the protein was incubated with the protein A coverslips for two hours followed by washing with PBS. All experiments except the measurements to determine χ(2) were carried out with the fundamental p-polarized and the second-harmonic beam unpolarized.
  • We chose Aladan (FIG. 1A) for this SHG study because of its absorption wavelength, large Stokes shift and difference dipole moment13. The peak absorbance of Aladan in buffer is 390 nm13 and the Δμ of its chromophore is large, variously estimated between 5 D15 and 20 D16. Aladan was dissolved in methanol and exposed to a freshly cleaved mica surface and allowed to adsorb in PBS. An SH background of 3500 cps was measured, due to the mica surface and to water polarized in its vicinity (χ(2) and χ(3) contributions, respectively17,18). After several hours, the signal with Aladan reached a plateau of ˜106 cps as shown in the SHG spectrum of 1C. The quadratic dependence of the SH signal on the fundamental power confirmed that Aladan is indeed SH-active. Two-photon-induced fluorescence, which appeared at ca. 550 nm, is well separated from the second harmonic light. Washing Aladan out of the well reverted the signal to the background level, demonstrating that the molecule adsorbs reversibly. The average orientation was determined by polarization measurements assuming a close packed monolayer of probe and a narrow orientational distribution. The SH intensity was measured as a function of input and output polarization to determine the nonlinear susceptibility elements χzzz (2), χzxx (2), and χxzx (2) 3,19. Ratios of the elements were used to calculate an average orientation of the probe on the mica surface of 48°. Power losses by the prism and the optics after the sample were taken into account in the calculation. The probe's nonlinear polarizability is estimated to be α(2)˜10−30 esu.
  • Next, Aladan mutants of the immunoglobulin-binding protein GB1 were used to show that an SH-active UAA can be used to detect protein on a surface. These Aladan-substituted proteins have previously been shown to fold and function similarly to wild-type GB113. Aladan was incorporated at two positions as shown in FIG. 1B: Ala24, a surface residue at the N-terminus of the helix and in proximity to the Fc binding surface, and Leu7, a buried residue in the first β strand. An X-ray structure of the Fab-GB1 complex previously showed that Fab fragment binds edge-on to this first β strand9. The Ala24 mutant was introduced into the well in contact with an aldehyde-derivatized coverslip. The SH signal immediately rose above the background as the GB1 lysines reacted with the aldehyde-derivatized surface (FIG. 2), reaching a plateau at about 30,000 cps. Wild-type GB1 produced no increase in the SH background upon addition (data not shown). The production of second-harmonic light by GB1-Aladan demonstrates that the protein self-orients to some degree upon binding to the surface, possibly due to the arrangement of lysines on the protein surface. The wavelength dependence of the signal shows the characteristic lineshape of the second-harmonic (FIG. 2B). The peak of Aladan absorption is ca. 390 nm, so the signal is resonantly enhanced. The SH signal after washing decreases slightly to 25,000 cps, indicating that some of the protein was reversibly bound to the surface.
  • We next wanted to test whether SHG could detect any conformational change upon addition of Fc to GB1. X-ray structures of the Fc-GB1 and Fab-GB1 complexes show no global conformational changes compared to the uncomplexed GB1, though the modest resolution (3.5 Å) of the Fc-GB1 complex would make subtle changes difficult to detect. For this experiment, we used glass coverslips with protein A covalently coupled to their surface. These coverslips were incubated with IgG, which binds to protein A via its Fc domain as shown in FIG. 3. After washing, GB1 with Aladan substituted at Ala24 was added for binding to the exposed IgG Fab domain, causing an increase in SH signal of ˜600 cps as shown in FIG. 4A. In a control experiment, addition of Ala24 mutant to protein A coverslips without IgG caused no increase in SH signal, indicating that GB1 binds specifically to IgG (data not shown). The much lower SH signal of GB1 bound to IgG-Protein A compared with to the aldehyde-derivatized surface is due to the reduced number of surface sites available for binding given the much larger size of the protein A-IgG complex than GB1 alone (>200 kDa for the complex vs. 6 kDa for GB1). Excess, unbound GB1 was then removed from the well by washing with PBS, but the SH signal remained constant. Addition of Fc causes a small and reproducible decrease in the SH signal (140±60 cps; 4 second average), which is detectable within the experimental noise, as shown in FIG. 4B. The SH signal of GB1-Aladan is remarkably stable over time on the protein-derivatized surfaces (no measurable change in signal over 10's of seconds) without the presence of an oxygen scavenger, indicating minimal photobleaching of the probe. As a control, Fc added to IgG-Protein A without GB1 produces no change in the SH background (data not shown). In another control, Aladan was incorporated at Leu7, a buried site away from the Fc binding region. No change in SH signal was observed upon adding Fc to this mutant bound to IgG-Protein A (FIG. 4C).
  • SHG is directly sensitive to molecular orientation on surfaces and—by applying it to biological molecules—can measure subtle structural changes. The present work is motivated by the goal of using the technique to measure conformational change in real time and space as a function of probe location. An unnatural SH-active amino acid, a class of probes we introduce here, is used to detect GB1 and its conformational change upon binding Fc. There are few techniques available to study structural motion of biomolecules in real space. Fluorescence resonance energy transfer (FRET) is useful for detecting conformational changes20-22, reporting on relative changes in distance and orientation between two site-specific probes, rather than absolute changes in structure. Other techniques, such as NMR and Raman spectroscopy, are useful for studying protein dynamics at a wide range of time scales23-25. These techniques rely on an interpretation of spectra to deduce structural changes and therefore do not provide direct real-space information, which may lead to uncertainty in model fitting. NMR has also traditionally been difficult to apply to larger biomolecules (e.g., >30 kDa) and membrane proteins, as well as on structural motions on slower, but functionally important, time scales (e.g., μs to ms). Environment-sensitive dyes have also been used to detect conformational changes, notably when a probe moves between polar and nonpolar environments, or whose distance from nearby quenchers changes20,26-28. SHG complements these techniques, for example, when it is difficult to incorporate multiple probes into a protein, or when the environment of a probe does not change appreciably with conformational change. SHG is relatively insensitive to quenching and to environmental changes, since it relies on a scattering process rather than emission. Most importantly, the technique is sensitive to absolute changes in probe orientation and has the potential to measure structural changes in real space and real time simultaneously. In the present study, we demonstrate that the free amino acid Aladan is SH-active by detecting it adsorbed to a mica surface. If the orientational distribution of Aladan is the same whether it is incorporated into GB1 or adsorbed directly to a surface, the expected difference in SH signal intensity between the two samples would be about two orders of magnitude apart since ISH α Ns 2; this is in rough agreement with the difference we measure. The signal strength in photons/pulse of surface SHG is governed by the following equation:

  • S≅(256π4 ω/hc 3) |N sα(2)|2 I 2 AT   (3)
  • I is the intensity of the fundamental beam incident at 45°, A is the beam cross section at the surface, T is the pulse duration, and ω is the second-harmonic frequency29. An regeneratively amplified system, of the type used to study ultrafast processes (e.g., μJ pulses)30, increases the SHG signal by several orders of magnitude. With Aladan's α(2) of ca. 10−30 esu, an amplified system, and standard noise reduction methods, the time resolution of the technique should be extendible to time scales of 10−6 s. To improve the time resolution, tighter focusing, higher fundamental peak power, or probes with higher nonlinear polarizability could be used. For example, a signal enhancement of about a factor of 5 could be achieved by tuning the incident angle of the fundamental to the critical angle31. Because the background is similar in magnitude to the GB1-Aladan signal and thus cannot be ignored, the relative phases of the various SH contributions must be known to quantitatively determine the absolute orientation of the probes or their angular change (Δ°) upon adding Fc.
  • Upon adding Fc to the surface-bound Ala24 GB1mutant, a small signal decrease occurs. Given the experimental noise levels in our set-up, the lower limit of this signal change is about 80 cps, indicating that a change in the average orientation of Aladan in GB1 occurs upon binding Fc. No observable change occurs in the same experiment with Aladan incorporated at Leu7 (FIG. 4C), so these experiments are consistent with a local conformational change of GB1 at the N-terminus of the GB1 helix, rather than a reorientation of the IgG-GB1 complex. Alternatively, following Equation 2, the average orientation of the probe at Leu7 may be much less sensitive to reorientation than when it is at Ala24. In this case, the observed change in SH signal could indicate a reorientation of the Fab-GB1 complex when binding to Fc rather than a local conformational change. Structures of both wild-type GB1 and the GB1-Fc complex have been reported, with no apparent structural differences outside of minor sidechain movements in the binding pocket formed largely by the helix, and the 3rd β, stance10. The Aladan substituted at Ala24 would be expected to reside just outside of the binding pocket, which extends to Glu27 on the helix. In contrast, there is no significant change in Ala24 Aladan fluorescence upon Fc binding (B. Cohen, unpublished data). Compared to UAA's, exogenous probes, such as spin labels or fluorophores attached via sidechain-reactive linkers, are expected to reside farther from the binding pocket and have greater ranges of motion28.
  • In this instance, SHG is able to detect a small signal change, a change not apparent in the protein by fluorescence or crystallography. With a highly oriented population of probes (and protein), the technique could resolve angular changes as small as 1° 1. GB1, bound to Fab on the surface, is the first study by SHG of a protein specifically ordered on a surface (FIG. 3). The GB1-Fab interaction has been defined crystallographically and is likely to produce an ordered array of GB1 on the mica surface in the present study9. Combined with the absolute homogeneity of labeling arising from site-specific Aladan incorporation, this could provide a level of sensitivity necessary to sense to a conformational change not previously detected by other techniques. Detection of conformational changes have also been obtained with an integrin protein (αvβ3) and amyloid proteins (β-amyloid and α-synuclein) (J. Salafsky, unpublished data). Another major goal of this research is to quantitatively map conformational change of a biomolecule in real time. To achieve this requires a narrow, or at least a Gaussian distribution of the probes (and thus the protein)32, and there are a variety of methods to specifically immobilize proteins to a surface (e.g., epitope tags, His-tags, antibody binding, etc.). Methods for orienting protein in 2-D in ways which preserve their functionality and freedom to move will be as indispensable to the technique as is growing crystals for X-ray studies. An important test for the technique is to measure the angular change that a site-specific probe undergoes upon ligand binding in a well defined system (e.g., maltose binding protein), and compare the result with that obtained by X-ray or NMR experiments.
  • The present invention discloses the use of unnatural amino acids which possess a hyperpolarizability for detecting proteins using a nonlinear technique such as second-harmonic generation. Henceforth, these specific unnatural amino acids will be referred to as SHAA's (‘Second-Harmonic-Amino-Acid’). One advantage of using unnatural amino acids (AA's) as probes of protein is that detection can be carried out in vivo—that is, in live cells. For example, the invention could be used to detect conformational change or protein activation in live cells in response to binding of ligands or drugs. The invention could be used for drug screening for compounds that induce or block conformational change in a protein, in the cellular milieu, or which bind, for example, to specific conformations of the protein. By using an oriented protein population, relative to a surface, a highly precise map of structure or conformational change in real space and real time could be built, which would be of use to basic research concerning questions such as protein folding, structure, function and dynamics. The invention optionally may include screening a plurality of compounds (e.g., candidate ligands, drugs, and/or modulators) by sequentially and/or simultaneously assessing their effects on conformation and/or other measurable parameters, for example, using a sample holder such as a microplate having a plurality of sample sites supporting a corresponding plurality of samples or sample systems.
  • In the case of in vivo detection, the cell itself orients the protein of interest, as, for instance, with membrane receptors and ion channels. This net orientation is a crucial requirement for detection by the nonlinear optical schemes employed in the present invention—such as second-harmonic generation or sum-frequency generation.
  • There is a large and growing body of literature which describes a number of methods for incorporating unnatural amino acids—including fluorescent ones—into a variety of proteins in both prokaryotes and eukaryotes. For example, the papers of Schultz and coworkers33,34, Dougherty and coworkers35,36 and references therein describe the field. U.S. Pat. No. 7,045,337 also describes in detail how unnatural amino acids can be incorporated in vivo. Furthermore, there has been a report in the literature of an unnatural amino acid that is a good candidate for possessing a hyperpolarizability (Aladan) based on its large fluorescence Stokes shift37. The SHAA can be incorporated into proteins in E. coli, a prokaryote, a mammalian cells, S. cerevisiae, etc. Multiple SHAA's can be incorporated into a single protein by techniques known to those skilled in the art.
  • Whether a given unnatural amino acid possesses a hyperpolarizability can be tested in a number of ways known to those skilled in the art. For example, it can be predicted to occur computationally, tested by incubating the molecule for propensity to generate second-harmonic light when it is contacted with an interface, measured using hyperrayleigh scattering, measured by an EFISH experiment, and so on. However, the final test to determine whether an unnatural amino acid possesses a hyperpolarizability is the presence of second-harmonic emission from the probe within the protein itself
  • One aspect of the present invention is the detection of a protein containing a SHAA by second-harmonic generation or sum-frequency generation: for example, detection in vitro at an interface, in vivo in cell membranes, or in vivo in the interior or the cells. With a well defined protein orientation, a protein's structure can be determined in real time and real space (e.g., conformational change detection) by measuring the tilt angle or absolute tilt angle of an unnatural amino acid probe, or a series of such probes, placed in different mutants of the protein. The probes can be incorporated at any site within the protein or at its termini, in any domain, etc. A third aspect of the invention includes a second-harmonic-active moiety or dye molecule that is chemically equipped to react covalently with an unnatural AA; for example, if the unnatural AA incorporated into a protein is Para-acetyl-phenylalanine (pAcF), the second-harmonic-active dye would have appropriate chemistry on it for bonding covalently to pAcF. A fourth aspect of the invention is the incorporation of a SHAA in addition to a second unnatural AA, the second unnatural AA (which will in general not be second-harmonic-active) allows chemically orthogonal covalent coupling of the protein in an oriented manner to a surface derivatized with appropriate chemistry for reaction with the second AA. With a highly oriented protein sample that is SH-active (using the two unnatural AA's), both the baseline SHG signal and the contrast (change in signal with conformational change) are larger.
  • Furthermore, a highly oriented protein population would enable the determination of the actual conformational change the SHAA undergoes upon conformational change, by determining the tilt angle of one or more probes at one or more sites within the protein as a function of time. The three-dimensional structure of a protein could be determined by making one or more mutants of a protein each containing a SHAA probe placed in a different location (i.e., the probe orientation relative to the surface in each mutant, and therefore the side-chain orientation, can be determined for the probe in each mutant and a model of the overall three dimensional protein structure could be built using this information). Information from steric hindrance methods, statistical methods, molecular dynamics, Ramachandran plots, or energy minimization methods known to those skilled in the art could be used to further aid in determining the structure given the measured probe tilt angles. A time-resolved measurement of the tilt angle of a probe produces a motion picture of a conformational change of a protein as it occurs in real time. Because of SHG's (and SFG's) virtually instantaneous response and sensitivity, spatial orientation of a particular probe (e.g., tilt angle or absolute tilt angle relative to a surface) could be measured in real time at almost any time scale of interest. Although the ideal probes could be unnatural amino acids, the present invention would also work with exogeneous dye probes that are well known in the state of the art (e.g., PyMPO-succinimidyl ester that couples to surface amines of a protein).
  • The use of an array of proteins on a surface would facilitate, for example, the rapid determination of conformational change in real time for basic research or drug screening, or the three-dimensional structure of a protein that is oriented on the surface, for example, by using a series of mutants arrayed on the surface, which each contain a SHAA probe in a different site of the protein. The absolute tilt angle of each probe can be determined using methods known to those skilled in the art. For example, the papers of Goh and Kemnitz and the papers that cite them describe how absolute tilt angles are measured38,39. The tilt angles of the probes in the different mutants, determined from their positions in the various sites in the mutant proteins, could thus be used to build a map of the protein's three-dimensional structure using techniques known to those skilled in the art, for example, by using computer modeling and energy minimization methods.
  • Second harmonic generation detection of a protein containing a SHAA is well known to those skilled in the art. The protein can be immobilized or adsorbed to a surface in such a way to produce a net orientation of the SHAA itself (its transition moment) and thus generate a source of second-harmonic radiation that can be detected in a straightforward manner. Conformational change of a protein containing a SHAA can be detected by adding ligands, drugs, etc. to the medium that is in contact with the surface (i.e., the interface) and monitoring a change in a physical property of the second-harmonic radiation (e.g., its intensity or polarization-dependence).
  • Important drug targets such as ion channels, integrins, kinases, receptors and GPCRs will all benefit from having a means of introducing a probe with a hyperpolarizability into them, without the need for chemical labeling in vitro. These mutant proteins could then be used for drug screening or basic research studies.
  • The SHAAs could, of course, also be used as probes of protein location or spatial dynamics within a cell. The present invention, of course, is not limited to proteins. Any biological molecule or entity into which an unnatural amino acid can be incorporated is covered by the scope of the invention.
  • For enzymes such as kinase or phosphatase protein40-48 important conformational changes occur in loop regions, such as in the activation loop upon binding ligands or drugs. As these loop regions are typically mobile, as exhibited by the lack of order in these regions in the proteins' X-ray-determined structure, it is expected that they will well tolerate amino acid substitutions and/or labeling in or near these regions. The loop regions are well known to those skilled in the art of determining or using the structures of the proteins. Moreover, catalytic function of a kinase requires a conformational change of the ‘activation loop’. As the active structures of kinase proteins across the kinome (there are about 500 distinct kinase proteins encoded by the human genome) are highly similar, drugs that target the active form of a kinase often are non-selective, reacting ‘off-target’ with other kinases. Loop regions that are well known in the art include catalytic loops, WPD loops, PTP loops, recognition loops and activation loops.
  • In this disclosure, a new class of probes is introduced—SH-active unnatural amino acids—and their use for detecting biomolecules and structural changes by SHG is demonstrated. Aladan is demonstrated to be SH-active by studying it alone on a surface and incorporated into a protein, GB1, rendering the protein detectable. A structural change is observed when an Fc fragment is introduced to GB1, labeled with Aladan at Ala24 and bound to IgG on a surface. No such change is observed if Aladan is substituted at Leu7 instead. These results are consistent with a local conformational change of GB1, a change undetectable by fluorescence or X-ray crystallography. SHG with SH-active exogenous labels or unnatural amino acid probes is promising as a structural technique with high angular and temporal resolution. With a narrowly oriented protein population appropriately labeled, the technique could be used to determine conformational change in real time and space, site-by-site.
  • EXAMPLES
  • The following examples further describe selected aspects and embodiments of the present disclosure. These examples and the various features and aspects thereof are included for illustration and are not intended to define or limit the entire scope of the present disclosure.
  • Example 1
  • An unnatural amino acid, Aladan, which possesses a hyperpolarizability, as determined by standard means known to those skilled in the art, is incorporated into maltose binding protein in E. coli, purified and expressed.
  • A baseline second-harmonic signal is generated using a Ti: Sapphire laser totally internally reflected from a suitable surface such as a polystyrene coverslip, available commercially from Newport Corp. or Coherent Inc. Details of the experimental set-up and recording of the data are described in Salafsky, 20063. The surface is mounted on and index-matched to a prism through which the fundamental and second-harmonic beams pass. A rubber gasket is placed on the surface to define a well with a volume of about 100 microliters. Aqueous buffer is added to the well. The wavelength of the fundamental is tuned to about 720 nm and the power is maximized. The SH baseline is recorded continuously using a filter to block the fundamental beam, a photomultiplier and single-photon detection.
  • The maltose binding protein, with the incorporated second-harmonic-active probe, is then added to the buffer. The protein will adsorb to the surface and generate a second-harmonic beam at about 360 nm, which is then recorded as an increase in signal from the buffer-surface interface. Thus, second-harmonic detection of a protein that has an unnatural amino acid with a hyperpolarizability (a SHAA) is accomplished, in this case in vitro.
  • Example 2
  • An unnatural amino acid that is second-harmonic active is incorporated into a single site in 10 different adenylate kinase mutants, each with the probe in a different site, according to procedures known to those skilled in the art. The protein mutants are isolated and purified according to standard means. The mutants are optionally screened for both activity and ability to generate second-harmonic radiation at an interface to determine the kinase that is both most native-like (e.g., in Km, Vmax, etc.) and also competent for generating second-harmonic radiation. For generating the second-harmonic radiation, the kinase proteins are adsorbed to a polystyrene surface.
  • Example 3
  • A series of mutants of maltose binding protein, which each possess a SHAA probe at a unique site, is created. A his-tag at the C-terminus is used to orient the protein on a Ni-NTA-bearing lipid bilayer according to protocols known to those skilled in the art. The mutant proteins containing the probes are bound to the bilayer specifically via the His-tag to create a defined, oriented population of protein. The absolute tilt angle of the probe in each mutant is measured according to well-established procedures. The tilt angles of the probes measured by SHG are used to create a three-dimensional model of the side-chain orientation and, by modeling, the three-dimensional structure of the entire protein. This SHG determined structure can be then compared with the X-ray crystal structure to heuristically improve the modeling, if necessary. Addition of lactose will induce a conformational change in the protein that can be resolved as a motion picture in real space and real time by measuring the absolute tilt angle of the probe in one or more of the mutants.
  • The disclosure set forth above may encompass multiple distinct inventions with independent utility. The disclosure relates information regarding specific embodiments, which are included for illustrative purposes, and which are not to be considered in a limiting sense, because numerous variations are possible. The inventive subject matter of the disclosure includes all novel and nonobvious combinations and subcombinations of the various elements, features, functions, and/or properties disclosed herein. The following claims particularly point out certain combinations and subcombinations regarded as novel and nonobvious. Inventions embodied in other combinations and subcombinations of features, functions, elements, and/or properties may be claimed in applications claiming priority from this or a related application. Such claims, whether directed to a different invention or to the same invention, and whether broader, narrower, equal, or different in scope to the original claims, also are regarded as included within the subject matter of the inventions of the present disclosure.
  • REFERENCES
    • (1) Salafsky, J. S. Journal of Chemical Physics 2006, 125, 074701.
    • (2) Salafsky, J. S. Physical Chemistry Chemical Physics 2007, 9, 5704.
    • (3) Heinz, T. F.; Tom, H. W. K.; Shen, Y. R. Physical Review A 1983, 28, 1883.
    • (4) Salafsky, J. S.; Eisenthal, K. B. Journal of Physical Chemistry B 2000, 104, 7752.
    • (5) Polizzi, M. A.; Plocinik, R. M.; Simpson, G. J. Journal of the American Chemical Society 2004, 126, 5001.
    • (6) Paszti, Z.; Wang, J.; Clarke, M. L.; Chen, Z. Journal of Physical Chemistry B 2004, 108, 7779.
    • (7) Clarke, M. L.; Wang, J.; Chen, Z. Journal of Physical Chemistry B 2005, 109, 22027.
    • (8) Kriech, M. A.; Conboy, J. C. Using the intrinsic chirality of a molecule as a label-free probe to detect molecular adsorption to a surface by second harmonic generation Applied Spectroscopy, 2005; Vol. 59; pp 746.
    • (9) Derrick, J. P.; Wigley, D. B. Nature 1992, 359, 752.
    • (10) Sauereriksson, A. E.; Kleywegt, G. J.; Uhl, M.; Jones, T. A. Structure 1995, 3, 265.
    • (11) Gronenborn, A. M.; Filpula, D. R.; Essig, N. Z.; Achari, A.; Whitlow, M.; Wingfield, P. T.; Clore, G. M. Science 1991, 253, 657.
    • (12) Achari, A.; Hale, S. P.; Howard, A. J.; Clore, G. M.; Gronenborn, A. M.; Hardman, K. D.; Whitlow, M. Biochemistry 1992, 31, 10449.
    • (13) Cohen, B. E.; McAnaney, T. B.; Park, E. S.; Jan, Y. N.; Boxer, S. G.; Jan, L. Y. Science 2002, 296, 1700.
    • (14) Abbyad, P.; Shi, X. H.; Childs, W.; McAnaney, T. B.; Cohen, B. E.; Boxer, S. G. Journal of Physical Chemistry B 2007, 111, 8269.
    • (15) Samanta, A.; Fessenden, R. W. Journal of Physical Chemistry A 2000, 104, 8972.
    • (16) Weber, G.; Farris, F. J. Biochemistry 1979, 18, 3075.
    • (17) Berkovic, G.; Shen, Y. R.; Marowsky, G.; Steinhoff, R. Journal of the Optical Society of America B- Optical Physics 1989, 6, 205.
    • (18) Ong, S. W.; Zhao, X. L.; Eisenthal, K. B. Chemical Physics Letters 1992, 191, 327.
    • (19) Heinz, T. F. Second-Order Nonlinear Optical Effects at Surfaces and Interfaces; Elsevier: Amsterdam, 1991.
    • (20) Glauner, K. S.; Mannuzzu, L. M.; Gandhi, C. S.; Isacoff, E. Y. Nature 1999, 402, 813.
    • (21) Cha, A.; Snyder, G. E.; Selvin, P. R.; Bezanilla, F. Nature 1999, 402, 809.
    • (22) Majumdar, D. S.; Smirnova, I.; Kasho, V.; Nir, E.; Kong, X. X.; Weiss, S.; Kaback, H. R.
  • Proceedings of the National Academy of Sciences of the United States of America 2007, 104, 12640.
    • (23) Thomas, G. J. J. Annual Review of Biophysics and Biomolecular Structure, 1999; Vol. 28; pp 1.
    • (24) Ishima, R.; Torchia, D. A. Protein dynamics from NMR Nature Structural Biology, 2000; Vol. 7; pp 740.
    • (25) Weljie, A. M.; Yamniuk, A. P.; Yoshino, H.; Izumi, Y.; Vogel, H. J. Protein conformational changes studied by diffusion NMR spectroscopy: Application to helix-loop-helix calcium binding proteins Protein Science, 2003; Vol. 12.
    • (26) Ghanouni, P.; Steenhuis, J. J.; Farrens, D. L.; Kobilka, B. K. Proceedings of the National Academy of Sciences of the United States of America 2001, 98, 5997.
    • (27) Weitzman, C.; Consler, T. G.; Kaback, H. R. Protein Science 1995, 4, 2310.
    • (28) Cohen, B. E.; Pralle, A.; Yao, X. J.; Swaminath, G.; Gandhi, C. S.; Jan, Y. N.; Kobilka,
  • B. K.; Isacoff, E. Y.; Jan, L. Y. Proceedings of the National Academy of Sciences of the United States of America 2005, 102, 965.
    • (29) Chen, C. K.; Heinz, T. F.; Ricard, D.; Shen, Y. R. Physical Review Letters 1981, 46, 1010.
    • (30) Zimdars, D.; Eisenthal, K. B. Static and Dynamic Solvation at the Air/Water Interface Journal of Physical Chemistry B, 2001; Vol. 105; pp 3993.
    • (31) Felderhof, B. U.; Bratz, A.; Marowsky, G.; Roders, O.; Sieverdes, F. Journal of the Optical Society of America B- Optical Physics 1993, 10, 1824.
    • (32) Feller, M. B.; Chen, W.; Shen, Y. R. Physical Review A 1991, 43, 6778.
    • (33) Xie, J. M. & Schultz, P. G. Innovation: A chemical toolkit for proteins—an expanded genetic code. Nature Reviews Molecular Cell Biology 7, 775-782 (2006).
    • (34) Summerer, D. et al. A genetically encoded fluorescent amino acid. Proceedings of the National Academy of Sciences of the United States of America 103, 9785-9789 (2006).
    • (35) Rodriguez, E. A., Lester, H. A. & Dougherty, D. A. In vivo incorporation of multiple unnatural amino acids through nonsense and frameshift suppression. Proceedings of the National Academy of Sciences of the United States of America 103, 8650-8655 (2006).
    • (36) England, P. M. Unnatural amino acid mutagenesis: A precise tool for probing protein structure and function. Biochemistry 43, 11623-11629 (2004).
    • (37) Cohen, B. E. et al. Probing protein electrostatics with a synthetic fluorescent amino acid. Science 296, 1700-1703 (2002).
    • (38) Goh, M. C. et al. Absolute Orientation of Water-Molecules at the Neat Water-Surface. Journal of Physical Chemistry 92, 5074-5075 (1988).
    • (39) Kemnitz, K. et al. The Phase of 2nd-Harmonic Light Generated at an Interface and Its Relation to Absolute Molecular-Orientation. Chemical Physics Letters 131, 285-290 (1986).
    • (40) Hubbard, S. R., Mohammadi, M. & Schlessinger, J. Autoregulatory mechanisms in protein-tyrosine kinases. Journal of Biological Chemistry 273, 11987-11990 (1998).
    • (41) Huse, M. & Kuriyan, J. The conformational plasticity of protein kinases. Cell 109, 275-282 (2002).
    • (42) Nagar, B. et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Research 62, 4236-4243 (2002).
    • (43) Noble, M. E. M., Endicott, J. A. & Johnson, L. N. Protein kinase inhibitors: Insights into drug design from structure. Science 303, 1800-1805 (2004).
    • (44) Seeliger, M. A. et al. High yield bacterial expression of active c-Abl and c-Src tyrosine kinases. Protein Science 14, 3135-3139 (2005).
    • (45) Sicheri, F. & Kuriyan, J. Structures of Src-family tyrosine kinases. Current Opinion in Structural Biology 7, 777-785 (1997).
    • (46) Sicheri, F., Moarefi, I. & Kuriyan, J. Crystal structure of the Src family tyrosine kinase Hck. Nature 385, 602-609 (1997).
    • (47) Xu, W. Q., Doshi, A., Lei, M., Eck, M. J. & Harrison, S. C. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Molecular Cell 3, 629-638 (1999).
    • (48) Xu, W. Q., Harrison, S. C. & Eck, M. J. Three-dimensional structure of the tyrosine kinase c-Src. Nature 385, 595-602 (1997).

Claims (21)

1-18. (canceled).
19. A method for determining if a local conformational change in the structure of a protein occurs upon exposing a protein to a second molecule, the method comprising:
(a) incorporating an unnatural amino acid into the protein;
(b) chemically coupling the protein of step (a) with a second harmonic (SH)-active or sum frequency (SF)-active moiety that is chemically equipped to react covalently with the unnatural amino acid;
(c) contacting the protein with an interface such that the SH-active or SF-active moiety has a net orientation at the interface;
(d) detecting light emitted using a surface-selective technique; and
(d) measuring a change in one or more physical properties of the emitted light upon exposing the protein to the second molecule, wherein the change in one or more physical properties of the emitted light indicates a local conformational change in the structure of the protein.
20. The method of claim 19, wherein the second molecule is a ligand, a compound, a small molecule, a drug, a peptide, an inhibitor, or a protein.
21. The method of claim 19, further comprising comparing the value of the one or more physical properties measured, with the value of the one or more physical properties measured in the absence of exposure to the second molecule.
22. The method of claim 19, wherein the protein is immobilized on a surface.
23. The method of claim 22, wherein the surface is a glass surface or mica.
24. The method of claim 19, wherein the unnatural amino acid is para-acetyl-phenylalanine (pAcF).
25. The method of claim 19, wherein the protein is an ion channel, an integrin, a kinase, a phosphatase, a receptor, or a G-protein coupled receptor (GPCR).
26. The method of claim 25, wherein the protein is a kinase or a phosphatase.
27. The method of claim 26, wherein a domain of the protein that undergoes a conformational change upon binding to a second molecule is a loop region.
28. The method of claim 27, wherein the loop region is a catalytic loop, a WPD loop, a PTP loop, a recognition loop, or an activation loop.
29. The method of claim 19, wherein the one or more physical properties of the emitted light comprise intensity or polarization dependence.
30. A method for determining if a local conformational change in the structure of a protein occurs upon exposing the protein to a second molecule, the method comprising:
(a) incorporating a first unnatural amino acid into the protein which is not SH-active or SF-active;
(b) incorporating a second unnatural amino acid into the protein which is not SH-active or SF-active;
(c) chemically coupling the protein with a second harmonic (SH)-active or sum frequency (SF)-active moiety that is chemically equipped to react covalently with the first unnatural amino acid to create a covalent bond;
(d) chemically coupling the protein in an oriented manner to a surface by reacting the second unnatural amino acid with the surface;
(d) detecting light emitted using a surface-selective technique; and
(e) measuring a change in one or more physical properties of the emitted light upon exposing the protein to the second molecule, wherein the change in one or more physical properties of the emitted light indicates a local conformational change in the structure of the protein.
31. The method of claim 30, wherein the second molecule is a ligand, a compound, a small molecule, a drug, a peptide, an inhibitor, or a protein.
32. The method of claim 30, further comprising comparing the value of the one or more physical properties measured, with the value of the one or more physical properties measured in the absence of exposure to the second molecule.
33. The method of claim 30, wherein the protein is an ion channel, an integrin, a kinase, a phosphatase, a receptor, or a G-protein coupled receptor (GPCR).
34. The method of claim 33, wherein the protein is a kinase or a phosphatase.
35. The method of claim 34, wherein a domain of the protein that undergoes a conformational change upon binding to a second molecule is a loop region.
36. The method of claim 35, wherein the loop region is a catalytic loop, a WPD loop, a PTP loop, a recognition loop, or an activation loop.
37. The method of claim 30, wherein the one or more physical properties of the emitted light comprise intensity or polarization dependence.
38. The method of claim 32, wherein the first unnatural amino acid is para-acetyl-phenylalanine (pAcF).
US15/840,958 2008-08-04 2017-12-13 Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability Abandoned US20180217150A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/840,958 US20180217150A1 (en) 2008-08-04 2017-12-13 Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13777308P 2008-08-04 2008-08-04
US12/535,631 US9182406B2 (en) 2008-08-04 2009-08-04 Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
US14/859,742 US9880172B2 (en) 2008-08-04 2015-09-21 Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
US15/840,958 US20180217150A1 (en) 2008-08-04 2017-12-13 Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/859,742 Continuation US9880172B2 (en) 2008-08-04 2015-09-21 Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability

Publications (1)

Publication Number Publication Date
US20180217150A1 true US20180217150A1 (en) 2018-08-02

Family

ID=42007419

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/535,631 Expired - Fee Related US9182406B2 (en) 2008-08-04 2009-08-04 Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
US14/859,742 Active US9880172B2 (en) 2008-08-04 2015-09-21 Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
US15/840,958 Abandoned US20180217150A1 (en) 2008-08-04 2017-12-13 Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US12/535,631 Expired - Fee Related US9182406B2 (en) 2008-08-04 2009-08-04 Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
US14/859,742 Active US9880172B2 (en) 2008-08-04 2015-09-21 Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability

Country Status (1)

Country Link
US (3) US9182406B2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10768174B2 (en) 2014-12-23 2020-09-08 Bluelight Therapeutics, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
US11486881B2 (en) 2016-05-09 2022-11-01 Quanta Therapeutics, Inc. Methods and devices for detection of peripheral membrane protein interactions using nonlinear optical techniques

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148391A1 (en) * 2002-01-24 2003-08-07 Salafsky Joshua S. Method using a nonlinear optical technique for detection of interactions involving a conformational change
US9182406B2 (en) 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
WO2012129347A1 (en) * 2011-03-21 2012-09-27 Biodesy, Llc Classification of kinase inhibitors using nonlinear optical techniques
US9395358B2 (en) 2012-02-05 2016-07-19 Biodesy, Inc. Methods for detecting allosteric modulators of protein
US20130288271A1 (en) 2012-04-25 2013-10-31 Biodesy, Llc Methods for detecting allosteric modulators of protein
US9938560B2 (en) 2012-02-05 2018-04-10 Biodesy, Inc. Methods for identifying modulators of Ras using nonlinear techniques
EP2841951B1 (en) * 2012-04-25 2019-12-11 Biodesy, Inc. Methods for detecting allosteric modulators of proteins
WO2014201435A1 (en) 2013-06-13 2014-12-18 Biodesy, Inc. Method of screening candidate biochemical entities targeting a target biochemical entity
WO2016003936A1 (en) 2014-06-30 2016-01-07 Biodesy, Inc. Systems and methods for high throughput analysis of conformation in biological entities
US10113965B2 (en) * 2015-03-06 2018-10-30 Purdue Research Foundation Methods for second harmonic generation imaging of protein crystals
CN107615047A (en) * 2015-04-02 2018-01-19 比奥德赛公司 The method for determining protein structure using surface selectivity nonlinear optical technique
WO2021142022A2 (en) 2020-01-06 2021-07-15 Quanta Therapeutics, Inc. Compositions and methods for identification of modulators of ras protein complexes

Family Cites Families (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3253065A (en) * 1963-08-07 1966-05-24 Bell Telephone Labor Inc Preparation of expanded polymers
DE2225546C3 (en) 1972-05-26 1979-01-04 Hoechst Ag, 6000 Frankfurt Water-insoluble azlactone dyes, process for their preparation and their use
JPS58182640A (en) 1982-04-20 1983-10-25 Hitachi Ltd Electrophotographic receptor of composite type
WO1984003506A1 (en) 1983-03-08 1984-09-13 Commw Serum Lab Commission Antigenically active amino acid sequences
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
JPS60500673A (en) 1983-03-08 1985-05-09 コモンウエルス セラム ラボラトリ−ズ コミツシヨン Amino acid sequence with antigenic activity
WO1986000138A1 (en) 1984-06-13 1986-01-03 Unilever Plc Devices for use in chemical test procedures
EP0184600B1 (en) * 1984-12-10 1990-03-14 Prutec Limited Method for optically ascertaining parameters of species in a liquid analyte
US4775637A (en) 1984-12-10 1988-10-04 Purtec Limited An immunoassay apparatus having at least two waveguides and method for its use
CH0229046H1 (en) * 1985-03-30 1998-07-15 Stuart Alan Kauffman METHOD FOR OBTAINING DNA, RNA, PEPTIDES, POLYPEPTINIQUE. DES OR PROTEINS BY MEANS OF A DNA RECOMBINANT TECH
NZ215865A (en) * 1985-04-22 1988-10-28 Commw Serum Lab Commission Method of determining the active site of a receptor-binding analogue
US4739044A (en) * 1985-06-13 1988-04-19 Amgen Method for derivitization of polynucleotides
US4757141A (en) * 1985-08-26 1988-07-12 Applied Biosystems, Incorporated Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof
US5236826A (en) * 1985-12-10 1993-08-17 Murex Corporation Immunoassay for the detection or quantitation of an analyte
US5252494A (en) 1986-06-25 1993-10-12 Trustees Of Tufts College Fiber optic sensors, apparatus, and detection methods using controlled release polymers and reagent formulations held within a polymeric reaction matrix
GB2197065A (en) * 1986-11-03 1988-05-11 Stc Plc Optical sensor device
US5763192A (en) * 1986-11-20 1998-06-09 Ixsys, Incorporated Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5079600A (en) * 1987-03-06 1992-01-07 Schnur Joel M High resolution patterning on solid substrates
WO1988007089A1 (en) * 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5231191A (en) * 1987-12-24 1993-07-27 Applied Biosystems, Inc. Rhodamine phosphoramidite compounds
US5266684A (en) * 1988-05-02 1993-11-30 The Reagents Of The University Of California Peptide mixtures
US5571689A (en) 1988-06-16 1996-11-05 Washington University Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid
US4959448A (en) * 1988-07-04 1990-09-25 Akzo N.V. Liquid crystalline side-chain polyesters prepared by polycondensation reactions
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US4997928A (en) * 1988-09-15 1991-03-05 E. I. Du Pont De Nemours And Company Fluorescent reagents for the preparation of 5'-tagged oligonucleotides
SE462408B (en) 1988-11-10 1990-06-18 Pharmacia Ab OPTICAL BIOSENSOR SYSTEM USING SURFACE MONITORING RESONSE FOR THE DETECTION OF A SPECIFIC BIOMOLIC CYCLE, TO CALIBRATE THE SENSOR DEVICE AND TO CORRECT FOUND BASELINE OPERATION IN THE SYSTEM
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5800992A (en) * 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5156810A (en) 1989-06-15 1992-10-20 Biocircuits Corporation Biosensors employing electrical, optical and mechanical signals
US5376556A (en) 1989-10-27 1994-12-27 Abbott Laboratories Surface-enhanced Raman spectroscopy immunoassay
US5215899A (en) * 1989-11-09 1993-06-01 Miles Inc. Nucleic acid amplification employing ligatable hairpin probe and transcription
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5145790A (en) * 1990-05-04 1992-09-08 Abbott Laboratories Reagents and method for detecting polychlorinated biphenyls
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
US5770434A (en) * 1990-09-28 1998-06-23 Ixsys Incorporated Soluble peptides having constrained, secondary conformation in solution and method of making same
JP3523252B2 (en) * 1990-11-21 2004-04-26 ホウテン ファーマシューティカルズ インコーポレイテッド Synthesis of equimolar multi-oligomer mixtures, especially oligopeptide mixtures
EP0564531B1 (en) * 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5320814A (en) * 1991-01-25 1994-06-14 Trustees Of Tufts College Fiber optic array sensors, apparatus, and methods for concurrently visualizing and chemically detecting multiple analytes of interest in a fluid sample
US5250264A (en) 1991-01-25 1993-10-05 Trustees Of Tufts College Method of making imaging fiber optic sensors to concurrently detect multiple analytes of interest in a fluid sample
US5244813A (en) * 1991-01-25 1993-09-14 Trustees Of Tufts College Fiber optic sensor, apparatus, and methods for detecting an organic analyte in a fluid or vapor sample
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5324633A (en) * 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
EP0566790B1 (en) * 1992-04-23 1996-08-07 Toda Kogyo Corp. Magnetic powder and magnetic toner
US5298741A (en) * 1993-01-13 1994-03-29 Trustees Of Tufts College Thin film fiber optic sensor array and apparatus for concurrent viewing and chemical sensing of a sample
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
JPH0739397A (en) 1993-08-04 1995-02-10 Kyowa Medex Co Ltd Method for determining chloride ion
US5599627A (en) * 1993-10-08 1997-02-04 Toda Kogyo Corporation Magnetic particles comprising magnetite core and process for producing the same
US5538848A (en) * 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
US5631734A (en) * 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5432610A (en) * 1994-04-15 1995-07-11 Hewlett-Packard Company Diode-pumped power build-up cavity for chemical sensing
EP0760012A4 (en) 1994-06-10 1997-07-02 Symbiotech Inc Method of detecting compounds utilizing genetically modified lambdoid bacteriophage
US5807522A (en) * 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US5485277A (en) * 1994-07-26 1996-01-16 Physical Optics Corporation Surface plasmon resonance sensor and methods for the utilization thereof
US5521289A (en) * 1994-07-29 1996-05-28 Nanoprobes, Inc. Small organometallic probes
US5627024A (en) * 1994-08-05 1997-05-06 The Scripps Research Institute Lambdoid bacteriophage vectors for expression and display of foreign proteins
US5512490A (en) * 1994-08-11 1996-04-30 Trustees Of Tufts College Optical sensor, optical sensing apparatus, and methods for detecting an analyte of interest using spectral recognition patterns
GB9508559D0 (en) 1995-04-27 1995-06-14 Polytech Transfer Ltd Surface second harmonic and sum-frequency generation immuno and enzyme assays
KR100407242B1 (en) * 1995-06-15 2004-04-13 토다 고교 가부시끼가이샤 Spherical Magnetic Particles for Magnetic Toner and Manufacturing Method Thereof
US5633724A (en) * 1995-08-29 1997-05-27 Hewlett-Packard Company Evanescent scanning of biochemical array
DE69628026T2 (en) 1995-09-07 2004-04-08 Novozymes A/S DETECTION OF THE ACTIVITY OF ENZYMES FOR DETERGENTS BY PHAGE.
GB9521943D0 (en) 1995-10-26 1996-01-03 Univ Hertfordshire Coded particles for process sequence tracking in combinatorial compound library preparation
US20010004528A1 (en) * 1995-11-14 2001-06-21 Stephen W. Fesik Use of 13c nuclear magnetic resonance to detect binding to target molecules
SE9504046D0 (en) 1995-11-14 1995-11-14 Pharmacia Ab Method of determining affinity and kinetic properties
US5814524A (en) * 1995-12-14 1998-09-29 Trustees Of Tufts College Optical sensor apparatus for far-field viewing and making optical analytical measurements at remote locations
US5847400A (en) 1996-02-01 1998-12-08 Molecular Dynamics, Inc. Fluorescence imaging system having reduced background fluorescence
DE69731084T2 (en) 1996-03-20 2006-02-23 Dyax Corp., Cambridge CLEANING OF TISSUE PLASMINOGENACTIVATOR (tPA)
US5900949A (en) * 1996-05-23 1999-05-04 Hewlett-Packard Company CCD imager for confocal scanning microscopy
CA2256449A1 (en) 1996-06-06 1997-12-11 Lajolla Pharmaceutical Company Apl immunoreactive peptides, conjugates thereof and methods of treatment for apl antibody-mediated pathologies
AU735015B2 (en) 1996-06-10 2001-06-28 Scripps Research Institute, The Use of substrate subtraction libraries to distinguish enzyme specificities
US5766905A (en) * 1996-06-14 1998-06-16 Associated Universities Inc. Cytoplasmic bacteriophage display system
US6055051A (en) * 1996-07-31 2000-04-25 The Trustees Of Columbia University In The City Of New York Method for determining surface properties of microparticles
US5821060A (en) 1996-08-02 1998-10-13 Atom Sciences, Inc. DNA sequencing, mapping, and diagnostic processes using hybridization chips and unlabeled DNA
EP0929361A4 (en) 1996-10-04 2000-07-19 Whatman Inc Device and method for simultaneous multiple chemical syntheses
AU4474497A (en) 1996-10-08 1998-05-05 U-Bisys B.V. Methods and means for selecting peptides and proteins having specific affinity for a target
JP2001503064A (en) 1996-11-06 2001-03-06 ジェネンテク,インコーポレイテッド Constrained helical peptides and their preparation
IL119586A (en) 1996-11-07 2001-09-13 Univ Ramot Discontinuous library of a single biological unit and a method for its preparation
IL119587A (en) 1996-11-07 2000-12-06 Univ Ramot Method of preparing and for obtaining bimolecular interactions
US5696157A (en) 1996-11-15 1997-12-09 Molecular Probes, Inc. Sulfonated derivatives of 7-aminocoumarin
US6699719B2 (en) * 1996-11-29 2004-03-02 Proteomic Systems, Inc. Biosensor arrays and methods
WO1998023948A1 (en) * 1996-11-29 1998-06-04 The Board Of Trustees Of The Leland Stanford Junior University Arrays of independently-addressable supported fluid bilayer membranes and methods of use thereof
SE9700384D0 (en) * 1997-02-04 1997-02-04 Biacore Ab Analytical method and apparatus
US6180415B1 (en) * 1997-02-20 2001-01-30 The Regents Of The University Of California Plasmon resonant particles, methods and apparatus
US6023540A (en) * 1997-03-14 2000-02-08 Trustees Of Tufts College Fiber optic sensor with encoded microspheres
WO1998051435A1 (en) 1997-05-14 1998-11-19 Weixin Tang Fully-coated, uniform-sized metallic particles
SE9702112D0 (en) 1997-06-04 1997-06-04 Holdingbolaget Vid Goeteborgs Method and apparatus for detection of a receptor antagonist
JPH11119270A (en) 1997-10-17 1999-04-30 Naoya Ogata Organic nonlinear optical material and its production
US6194222B1 (en) * 1998-01-05 2001-02-27 Biosite Diagnostics, Inc. Methods for monitoring the status of assays and immunoassays
US6410245B1 (en) * 1998-04-01 2002-06-25 Affymax, Inc. Compositions and methods for detecting ligand-dependent nuclear receptor and coactivator interactions
DK1068241T3 (en) 1998-04-02 2008-02-04 Genentech Inc Antibody variants and fragments thereof
US6040586A (en) * 1998-05-05 2000-03-21 The Perkin-Elmer Corporation Method and system for velocity-normalized position-based scanning
US6284197B1 (en) * 1998-06-05 2001-09-04 The Regents Of The University Of California Optical amplification of molecular interactions using liquid crystals
IL124903A0 (en) * 1998-06-15 1999-01-26 Bauer Alan Josef An enzyme biosensor
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6576478B1 (en) * 1998-07-14 2003-06-10 Zyomyx, Inc. Microdevices for high-throughput screening of biomolecules
US6682942B1 (en) * 1998-07-14 2004-01-27 Zyomyx, Inc. Microdevices for screening biomolecules
US6121983A (en) * 1998-11-19 2000-09-19 Xerox Corporation Method and apparatus for a solid state laser scanning architecture
CA2355215A1 (en) 1998-12-28 2000-07-06 Jim Wells Identifying small organic molecule ligands for binding
EP1157144A4 (en) 1999-01-13 2010-04-28 Cornell Res Foundation Inc Monolithic fabrication of fluidic structures
US6134002A (en) 1999-01-14 2000-10-17 Duke University Apparatus and method for the rapid spectral resolution of confocal images
US6095555A (en) * 1999-05-12 2000-08-01 Trw Inc. Apparatus for sensing a forward position of a vehicle seat
US7056661B2 (en) 1999-05-19 2006-06-06 Cornell Research Foundation, Inc. Method for sequencing nucleic acid molecules
US7350236B1 (en) 1999-05-25 2008-03-25 Silverbrook Research Pty Ltd Method and system for creation and use of a photo album
GB9923644D0 (en) * 1999-10-06 1999-12-08 Medical Biosystems Ltd DNA sequencing
US6456423B1 (en) 1999-10-22 2002-09-24 The Board Of Trustees Of The University Of Illinois Silicon nanoparticle microcrystal nonlinear optical devices
US7108970B2 (en) 2000-01-07 2006-09-19 Transform Pharmaceuticals, Inc. Rapid identification of conditions, compounds, or compositions that inhibit, prevent, induce, modify, or reverse transitions of physical state
US6917726B2 (en) 2001-09-27 2005-07-12 Cornell Research Foundation, Inc. Zero-mode clad waveguides for performing spectroscopy with confined effective observation volumes
US7193711B2 (en) * 2000-07-11 2007-03-20 Maven Technologies, Llc Imaging method and apparatus
US7126688B2 (en) 2000-07-11 2006-10-24 Maven Technologies, Llc Microarray scanning
US6833920B2 (en) * 2000-07-11 2004-12-21 Maven Technologies Llc Apparatus and method for imaging
US7023547B2 (en) 2000-07-11 2006-04-04 Maven Technologies, Llc Apparatus including a biochip for imaging of biological samples and method
US20020094528A1 (en) 2000-11-29 2002-07-18 Salafsky Joshua S. Method and apparatus using a surface-selective nonlinear optical technique for detection of probe-target interations
IL156114A0 (en) 2000-11-29 2003-12-23 Joshua S Salafsky Method and apparatus using a surface-selective nonlinear optical technique for detection of probe-target interactions
US6953694B2 (en) * 2000-12-06 2005-10-11 The Trustees Of Columbia University In The City Of New York Attachment of second harmonic-active moiety to molecules for detection of molecules at interfaces
US20020127563A1 (en) 2001-01-08 2002-09-12 Salafsky Joshua S. Method and apparatus using a surface-selective nonlinear optical technique for detection of probe-target interactions without labels
US20050118731A1 (en) * 2001-01-08 2005-06-02 Salafsky Joshua S. Method and apparatus using a surface-selective nonlinear optical technique for detection of probe-target interactions without labels
EP1356036B1 (en) * 2001-01-25 2008-05-07 Anthony C. Forster Process and compositions for peptide, protein and peptidomimetic synthesis
EP1364204A1 (en) 2001-02-01 2003-11-26 Joshua S. Salafsky Designs of labels for detection with a surface-selective nonlinear optical technique
SE0100889D0 (en) * 2001-03-14 2001-03-14 Biacore Ab Method and apparatus for attenuated total reflection spectrosopy
US7316769B2 (en) 2001-03-19 2008-01-08 Cornell Research Foundation, Inc. Length-dependent recoil separation of long molecules
EP2796546B1 (en) * 2001-04-19 2017-08-09 The Scripps Research Institute Incorporation of unnatural amino acids
US7384773B1 (en) * 2001-05-10 2008-06-10 Pfizer Inc Crystal of HIV protease-cleaved human beta secretase and method for crystallization thereof
GB0112238D0 (en) 2001-05-18 2001-07-11 Medical Biosystems Ltd Sequencing method
US20040146460A1 (en) 2001-07-17 2004-07-29 Salafsky Joshua S Design of labels for detection with a surface-seletive nonlinear optical technique
WO2003064991A2 (en) 2001-07-17 2003-08-07 Salafsky Joshua S Method and apparatus using a nonlinear optical technique for detection of probe-target interactions in a field
US7473361B2 (en) 2001-11-30 2009-01-06 Cornell Research Foundation Diffusion-based molecular separation in structured microfluidic devices
WO2003055379A2 (en) 2001-12-24 2003-07-10 Salafsky Joshua S Method using a surface-selective nonlinear optical technique for imaging of biological samples
GB0200938D0 (en) * 2002-01-16 2002-03-06 Solexa Ltd Prism design for scanning applications
US20030148391A1 (en) * 2002-01-24 2003-08-07 Salafsky Joshua S. Method using a nonlinear optical technique for detection of interactions involving a conformational change
US7545494B2 (en) * 2003-07-23 2009-06-09 Bayer Technology Services Gmbh Analytical system and method for analyzing nonlinear optical signals
WO2005052644A2 (en) * 2003-11-21 2005-06-09 Perkinelmer Las, Inc. Optical device integrated with well
US7336359B1 (en) 2004-05-03 2008-02-26 Purdue Research Foundation System and method for nonlinear optical null ellipsometry
US7470549B2 (en) 2004-05-26 2008-12-30 Fujifilm Corporation Measurement method using biosensor
KR100647287B1 (en) * 2004-08-31 2006-11-23 삼성에스디아이 주식회사 Polymer electrolyte membrane and fuel cell employing the same
JP2006090782A (en) 2004-09-22 2006-04-06 Fyuuensu:Kk Method for detecting structural change of protein fixed on substrate
JP4580291B2 (en) * 2005-06-30 2010-11-10 富士フイルム株式会社 Measuring method using biosensor
US8062900B2 (en) 2005-12-30 2011-11-22 Corning Incorporated Optically readable microplate
WO2007079752A2 (en) * 2006-01-11 2007-07-19 Novo Nordisk A/S Improved spherical encoded beads
US7406222B2 (en) * 2006-02-16 2008-07-29 Pavel Kornilovich Composite evanescent waveguides and associated methods
JP4664221B2 (en) * 2006-03-20 2011-04-06 富士フイルム株式会社 Sensor unit and total reflection prism
US7709808B2 (en) * 2006-05-16 2010-05-04 Applied Biosystems, Llc Systems, methods and apparatus for single molecule sequencing
US8039270B2 (en) 2008-05-22 2011-10-18 Maven Technologies, Llc Apparatus and method for performing ligand binding assays on microarrays in multiwell plates
US9182406B2 (en) 2008-08-04 2015-11-10 Biodesy, Inc. Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
US8355133B2 (en) * 2009-12-30 2013-01-15 Maven Technologies, Llc Biological testing with sawtooth-shaped prisms
US20120202296A1 (en) * 2011-02-02 2012-08-09 The Trustees Of Columbia University In The City Of New York System, method, and apparatus for measuring affinity constants
WO2012129347A1 (en) 2011-03-21 2012-09-27 Biodesy, Llc Classification of kinase inhibitors using nonlinear optical techniques
US9221919B2 (en) * 2011-11-21 2015-12-29 California Institute Of Technology Functionalization of and use of functionalized second harmonic generating nanoprobes
US20130288271A1 (en) 2012-04-25 2013-10-31 Biodesy, Llc Methods for detecting allosteric modulators of protein
US9938560B2 (en) 2012-02-05 2018-04-10 Biodesy, Inc. Methods for identifying modulators of Ras using nonlinear techniques
EP2841951B1 (en) 2012-04-25 2019-12-11 Biodesy, Inc. Methods for detecting allosteric modulators of proteins
WO2014201435A1 (en) 2013-06-13 2014-12-18 Biodesy, Inc. Method of screening candidate biochemical entities targeting a target biochemical entity

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10768174B2 (en) 2014-12-23 2020-09-08 Bluelight Therapeutics, Inc. Attachment of proteins to interfaces for use in nonlinear optical detection
US11486881B2 (en) 2016-05-09 2022-11-01 Quanta Therapeutics, Inc. Methods and devices for detection of peripheral membrane protein interactions using nonlinear optical techniques

Also Published As

Publication number Publication date
US9182406B2 (en) 2015-11-10
US20160077099A1 (en) 2016-03-17
US9880172B2 (en) 2018-01-30
US20100068144A1 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
US9880172B2 (en) Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
Renaud et al. Biophysics in drug discovery: impact, challenges and opportunities
Huber et al. Biomolecular interaction analysis in drug discovery using surface plasmon resonance technology
Jameson et al. Fluorescence polarization/anisotropy in diagnostics and imaging
Herron et al. Physical methods to characterize pharmaceutical proteins
Royer et al. Fluorescence approaches to quantifying biomolecular interactions
Royer Probing protein folding and conformational transitions with fluorescence
US10672502B2 (en) Methods for determining protein structure using a surface-selective nonlinear optical technique
US20200132604A1 (en) Methods of determining protein structure using two-photon fluorescence measurements
Fechner et al. Size does matter! Label-free detection of small molecule–protein interaction
Hunt et al. A fluorescent biosensor reveals conformational changes in human immunoglobulin E Fc: implications for mechanisms of receptor binding, inhibition, and allergen recognition
Giliberti et al. Heterogeneity of the transmembrane protein conformation in purple membranes identified by infrared nanospectroscopy
Stumpf et al. Optical probes based on G protein‐coupled receptors–added work or added value?
US20230258650A1 (en) Methods and devices for detection of peripheral membrane protein interactions using nonlinear optical techniques
Salafsky Detection of protein conformational change by optical second-harmonic generation
US10768174B2 (en) Attachment of proteins to interfaces for use in nonlinear optical detection
Salafsky Second-harmonic generation for studying structural motion of biological molecules in real time and space
Kempe et al. Accurate fluorescence quantum yield determination by fluorescence correlation spectroscopy
Güldenhaupt et al. Secondary structure of lipidated Ras bound to a lipid bilayer
Qiao et al. Enhanced fluorescence anisotropy assay for human cardiac troponin I and T detection
Gesellchen et al. Direct optical detection of protein-ligand interactions
Bondar et al. Optical sensors of heterotrimeric G protein signaling
Laptenok et al. Disentangling picosecond events that complicate the quantitative use of the calcium sensor YC3. 60
Salafsky et al. A second-harmonic-active unnatural amino acid as a structural probe of biomolecules on surfaces
ES2964573T3 (en) Block Exact FRET

Legal Events

Date Code Title Description
AS Assignment

Owner name: BIODESY, LLC, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SALAFSKY, JOSHUA S.;REEL/FRAME:044390/0293

Effective date: 20120607

Owner name: BIODESY, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIODESY, LLC;REEL/FRAME:044865/0418

Effective date: 20131011

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: BLUELIGHT THERAPEUTICS, INC., CALIFORNIA

Free format text: CHANGE OF NAME;ASSIGNOR:BIODESY, INC.;REEL/FRAME:053834/0130

Effective date: 20200520